This activity was planned to meet the educational needs of pharmacists, oncology and non-oncology physicians, physician associates, nurse practitioners and nurses who practice in hospitals, health systems, ambulatory clinics, and infusion centers who care for or are interested in the care of patients treated with immune checkpoint inhibitors.
At the conclusion of this activity, participants should be able to:
- Describe mechanisms of action of immune checkpoint inhibitors (ICIs) and how they relate to the pathophysiology of immune-related adverse events (irAEs).
- Determine best methods to address potential ICI drug interactions based on current and emerging data.
- Evaluate strategies for diagnosis and management of irAEs.
- Develop interprofessional, evidence-based care plans for patients receiving ICIs who require irAE management taking into account patient-specific factors.
Welcome and Introductions
Jordan McPherson
Background/Mechanism of ICIs, Comparison to Other Treatment Toxicities
Jordan McPherson
Current and Emerging Evidence Surrounding Drug Interactions of Immune Checkpoint Inhibitors (ICIs) and their Influence on ICI Safety and Efficacy
Jordan McPherson
Pathophysiology of Immune-related Adverse Events (irAEs) and General irAE Management Principles
Jordan McPherson
Management of Common irAEs and Rare Serious irAEs
Pauline Funchain
Patient Cases: Best Practices for Early irAE Identification/Management
All Faculty
Faculty Discussion, Questions and Answers
All Faculty
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
- Pauline Funchain - Research Grant: Ideaya, Linneaus
Consultant: Immunocore, Sanofi
Advisor: Tempus
All other persons in control of content do not have any relevant financial relationships with an ineligible company. As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
This activity consists of recordings of faculty slides presentations, active learning activities, discussion, and handouts. Participants must participate in the activity in its entirety to claim continuing pharmacy education credit online at ASHP Learning Center. Follow the prompts online to complete the evaluation, claim credit and view the statement of credit immediately after completing the activity.
- CPE: Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.
- CNE: In order to receive nursing contact hours, you will need to complete the entire learning activity and submit an evaluation form.
Patients taking immune checkpoint inhibitors (ICIs) are seen throughout all practice settings due to their impact on cancer survival and indications throughout many cancer types. ICIs have the potential to cause immune-related adverse events (irAEs), which can be a diagnostic and therapeutic challenge. This activity will discuss early identification and management irAEs to prevent progression leading to severe adverse effects and to avoid interruptions in life-prolonging ICI therapy. It is imperative that physicians, pharmacists, physician associates, nurse practitioners and nurses apply evidence-based guideline recommendations to patient-specific care plans to improve overall patient outcomes.
